Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens.

Bone marrow transplantation·2009

Same author

Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results.

Bone marrow transplantation·2008

Same author

Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.

Bone marrow transplantation·2008

Same author

Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2007

Same author

Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes.

Annals of oncology : official journal of the European Society for Medical Oncology·2006

Same author

Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia.

Leukemia & lymphoma·2006

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Patient Derived Cell Culture and Isolation of CD133⁺ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

CD133 (AC133) expression on AML cells and progenitors.

S M Vercauteren¹, H J Sutherland

¹Terry Fox Laboratory, British Columbia Cancer Agency Vancouver Hospital and Health Sciences Centre, Vancouver, BC Canada.

|April 16, 2002

Summary

CD133 expression does not predict outcomes in acute myeloid leukemia (AML). While CD133 marks primitive leukemic progenitors in vitro, it cannot be used to isolate them in vivo.

Area of Science:

Hematology
Cancer Biology
Cellular Hierarchy

Background:

Acute myeloid leukemia (AML) exhibits a hierarchy of progenitor cells with varying functional capabilities.
CD133 (AC133) is a transmembrane protein found on normal hematopoietic progenitors (CD34(+) and CD34(-)).
This study investigates the prognostic value of CD133 expression in AML and its presence on disease-maintaining AML progenitors.

Purpose of the Study:

To determine the prognostic significance of CD133 expression in acute myeloid leukemia (AML).
To characterize the expression of CD133 on AML progenitors responsible for disease maintenance.
To assess the utility of CD133 for purifying primitive leukemic progenitors.

Main Methods:

Analysis of CD133 and CD34 expression in AML cells from 102 patients.

More Related Videos

Isolation and Enrichment of Liver Progenitor Subsets Identified by a Novel Surface Marker Combination

Isolation and Enrichment of Liver Progenitor Subsets Identified by a Novel Surface Marker Combination

Published on: February 18, 2017

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

Related Experiment Videos

Last Updated: Jul 13, 2026

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Patient Derived Cell Culture and Isolation of CD133⁺ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

Isolation and Enrichment of Liver Progenitor Subsets Identified by a Novel Surface Marker Combination

Isolation and Enrichment of Liver Progenitor Subsets Identified by a Novel Surface Marker Combination

Published on: February 18, 2017

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

Correlation of CD133/CD34 expression with clinical outcomes in 92 treated AML patients.

Flow cytometry sorting of AML cells into CD34/CD133 subfractions for in vitro (CFU, SC) and in vivo (NOD/SCID mice) assays.

Main Results:

CD133 expression did not correlate with survival, FAB subtype, cytogenetics, or white blood cell count (WBCC) in AML.
CD133 expression was correlated with CD34 expression.
Leukemic progenitors capable of forming colonies (CFU) and engrafting immunodeficient mice (NOD/SCID) were found across all CD34/CD133 subfractions, including CD34(-)/CD133(-).

Conclusions:

CD133 is not a reliable prognostic marker for AML.
CD133 is co-expressed with CD34 on primitive leukemic progenitors detected in vitro.
CD133 alone cannot be used to purify in vivo leukemic progenitors in AML patients.